Health TrialsbyHealthPanel

Glioma, Recurrent High Grade

2

Review clinical trials related to Glioma, Recurrent High Grade. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study of NST-628 in Recurrent Grade 4 Glioma

This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high phosphorylated extracellular signal-regulated kinase (pERK) expression who are scheduled for surgical resection. This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability, and anti-tumor activity of NST-628.

Participants needed: 12
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nader SanaiUpdated: Sep 15, 2026Locations: 1
Eligibility criteria

1. Diagnosed with Grade 4 glioma, who have progressed on or following standard o... [+12]

1. Has extracranial disease, or evidence of leptomeningeal disease. [+10]

Read more
Status: Recruiting

BC008-1A Injection for Recurrent CNS WHO G4 Glioma

The purpose of this Phase I clinical study is to evaluate the safety, preliminary efficacy and pharmacokinetic characteristics of BC008-1A injection in subjects with recurrent CNS WHO grade 4 glioma. This is a randomized and open-label study, with two dose groups set up, and 10 to 20 subjects will be enrolled in each group.

Participants needed: 40
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.Updated: Jul 9, 2025Locations: 1
Eligibility criteria

Voluntarily sign the informed consent form; [+10]

Having been previously exposed to any anti-TIGIT, PD-1, PD-L1 or CTLA-4 drugs; [+17]

Read more